Neuroimaging in patients with COVID-19: a neuroradiology expert group consensus

Eur Radiol. 2022 Jun;32(6):3716-3725. doi: 10.1007/s00330-021-08499-0. Epub 2022 Jan 19.

Abstract

Neurological and neuroradiological manifestations in patients with COVID-19 have been extensively reported. Available imaging data are, however, very heterogeneous. Hence, there is a growing need to standardise clinical indications for neuroimaging, MRI acquisition protocols, and necessity of follow-up examinations. A NeuroCovid working group with experts in the field of neuroimaging in COVID-19 has been constituted under the aegis of the Subspecialty Committee on Diagnostic Neuroradiology of the European Society of Neuroradiology (ESNR). The initial objectives of this NeuroCovid working group are to address the standardisation of the imaging in patients with neurological manifestations of COVID-19 and to give advice based on expert opinion with the aim of improving the quality of patient care and ensure high quality of any future clinical studies. KEY POINTS: • In patients with COVID-19 and neurological manifestations, neuroimaging should be performed in order to detect underlying causal pathology. • The basic MRI recommended protocol includes T2-weighted, FLAIR (preferably 3D), and diffusion-weighted images, as well as haemorrhage-sensitive sequence (preferably SWI), and at least for the initial investigation pre and post-contrast T1 weighted-images. • 3D FLAIR should be acquired after gadolinium administration in order to optimise the detection of leptomeningeal contrast enhancement.

Keywords: COVID-19; CT; MRI; Neuroimaging.

MeSH terms

  • COVID-19*
  • Consensus
  • Gadolinium
  • Humans
  • Magnetic Resonance Imaging / methods
  • Neuroimaging / methods

Substances

  • Gadolinium